Article Sidebar
Views PDF: 245
OUTCOME OF TS-1 BASED REGIMENS FOR ADVANCED GASTRIC CANCER
Main Article Content
Abstract
Objective: Evaluating the treatment outcomes of chemotherapy with TS-1 for advanced gastric cancer. Patients and method: 43 advanced gastric cancer patients, 31 patients were assigned to TS-1 plus Cisplatin and 12 patients were assigned to TS-1 alone regimes at K Hospital and Bach Mai Hospital from January 2020 to April 2021. Results: The mean age of study group was 60.1 years. 88.4% patients had good performance status PS=0-1. In the TS-1 plus Cisplatin group, 51.6% patients had total responses, no completed response, 35.5% patients had stable disease and 4% patients had progressive disease. In the TS-1 alone group, 16.7% patients had total responses, no completed response, 66.6% patients had stable disease and 2% patients had progressive disease. Conclusion: TS-1 has some effect on controlling advanced gastric cancer.
Article Details
Keywords
advanced gastric cancer, TS-1, chemothepary
References
2. GLOBOCAN Cancer fact sheets: stomach (2020). https://gco.iarc.fr/today/data/factsheets/cancers/7-Stomach-fact-sheet.pdf
3. Koizumi W, Narahara H, Hara T, Takagane A, Akiya T, Takagi M, et al (2008). TS-1 plus cisplatin versusTS-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): A phase III trial. Lancet Oncol, 9, 215–21.
4. Nguyễn Minh Phương (2020). Đánh giá kết quả phác đồ TS-1 – Cispaltin trong điều trị bước một ung thư dạ dày giai đoạn muộn tại bệnh viện K. Trường Đại học Y Hà Nội.
5. Ter Veer, E. et al. The efficacy and safety of S-1-based regimens in the first-line treatment of advanced gastric cancer: a systematic review and meta-analysis. Gastric Cancer 19, 696–712 (2016).